Sugi Predict

Sugi Predict / Compounds / SCHEMBL1136065

SCHEMBL1136065

SCHEMBL1136065

O=C(NC[C@H](O)CO)c1ccc(Cl)s1

nearest known ligand 0.59

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.52
▸ HPGD P15428 2/20 0.50
▸ TSHR P16473 2/20 0.50
▸ CA2 P00918 1/20 0.46
▸ F10 P00742 3/20 0.45
▸ GSK3B P49841 1/20 0.45
▸ LMNA P02545 2/20 0.45
▸ F2 P00734 1/20 0.44
▸ DAO P14920 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1136066 1.00 MAPK1 (0.52) MAPK1HPGDTSHRCA2F10
SCHEMBL15221118 1.00 MAPK1 (0.52) MAPK1HPGDTSHRCA2F10
SCHEMBL16416468 0.88 MAPK1 (0.52) MAPK1HPGDTSHRF10GSK3B
SCHEMBL14830273 0.88 MAPK1 (0.52) MAPK1HPGDTSHRF10GSK3B
SCHEMBL12348258 0.86 MAPK1 (0.51) MAPK1HPGDTSHRF10GSK3B
SCHEMBL14838637 0.86 MAPK1 (0.51) MAPK1HPGDTSHRF10GSK3B
SCHEMBL498073 0.86 MAPK1 (0.51) MAPK1HPGDTSHRF10GSK3B
SCHEMBL469776 0.86 MAPK1 (0.51) MAPK1HPGDTSHRF10GSK3B
SCHEMBL78371 0.86 MAPK1 (0.51) MAPK1HPGDTSHRF10GSK3B
SCHEMBL28025617 0.86 MAPK1 (0.51) MAPK1HPGDTSHRF10GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583761-B1 METHOD FOR PRODUCING 5-CHLORO- i N /i -({5 i S /i )-2-OXO-3- 4-(3-OXO-4-MORPHOLINYL)-PHENYL -1,3-OXAZOLIDIN-5-YL&rc ub;-METHYL)-2-THIOPHENE CARBOXAMIDE BAYER SCHERING PHARMA AG (DE) 2011-02-23 — — EP claimed
WO-2023088229-A1 METHOD FOR SYNTHESIZING RIVAROXABAN 浙江华海药业股份有限公司 2023-05-25 — — WO disclosed
EP-2705028-B1 PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS EGYT GYOGYSZERVEGYESZETI GYAR (HU) 2019-08-21 — — EP disclosed
US-20170267669-A1 Process for the Preparation of Rivaroxaban CIPLA LIMITED (IN) 2017-09-21 — — US disclosed
US-9598403-B2 Process for the preparation of rivaroxaban AMNEAL PHARMACEUTICALS LLC (US) 2017-03-21 — — US disclosed
US-9556163-B2 Process for the preparation of a rivaroxaban and intermediates formed in said process EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2017-01-31 — — US disclosed
US-9394292-B2 Rivaroxaban intermediate and preparation thereof WANBURY LTD. (IN) 2016-07-19 — — US disclosed
US-9394292-B2 Rivaroxaban intermediate and preparation thereof WANBURY LTD. (IN) 2016-07-19 — — US disclosed
US-20160194309-A1 A Process For The Preparation Of Rivaroxaban AMNEAL PHARMACEUTICALS LLC 2016-07-07 — — US disclosed
US-20150299175-A1 RIVAROXABAN INTERMEDIATE AND PREPARATION THEREOF WANBURY LTD. (IN) 2015-10-22 — — US disclosed
WO-2009007026-A1 AMINOACYL PRODRUGS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 — — WO disclosed
WO-2008155034-A1 SUBSTITUTED OXAZOLIDINONES AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-24 — — WO disclosed
US-7351823-B2 Preparation process BAYER HEALTHCARE AG (DE) 2008-04-01 — — US disclosed
US-7351823-B2 Preparation process BAYER HEALTHCARE AG (DE) 2008-04-01 — — US disclosed
US-20070149522-A1 Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide BAYER HEALTHCARE AG (DE) 2007-06-28 — — US disclosed
US-20070149522-A1 Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide BAYER HEALTHCARE AG (DE) 2007-06-28 — — US disclosed
US-20070066615-A1 Heterocyclic compounds BAYER HEATHCARE AG (DE) 2007-03-22 — — US disclosed
US-20070066615-A1 Heterocyclic compounds BAYER HEATHCARE AG (DE) 2007-03-22 — — US disclosed
US-20070066615-A1 Heterocyclic compounds BAYER HEATHCARE AG (DE) 2007-03-22 — — US disclosed
WO-2004060887-A1 METHOD FOR PRODUCING 5-CHLORO-N-({5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)-PHENYL]-1,3-OXAZOLIDIN-5-YL}-METHYL)-2-THIOPHENE CARBOXAMIDE BAYER HEALTHCARE AG (DE) 2004-07-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149522-A1 Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide NT5C, NOX5, MT-ND5 MAPK1 4432/4885HPGD 1313/4885TSHR 2837/4885
US-20160194309-A1 A Process For The Preparation Of Rivaroxaban TFPI, VKORC1, VKORC1L1 MAPK1 2762/4885HPGD 481/4885TSHR 2132/4885
US-20170267669-A1 Process for the Preparation of Rivaroxaban F7, F5, F2 MAPK1 2591/4885HPGD 608/4885TSHR 3124/4885
US-20070066615-A1 Heterocyclic compounds F2, SERPINC1, TFPI MAPK1 3699/4885HPGD 25/4885TSHR 3344/4885
US-20150299175-A1 RIVAROXABAN INTERMEDIATE AND PREPARATION THEREOF VKORC1L1, VKORC1, CYP3A5 MAPK1 2932/4885HPGD 713/4885TSHR 2032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.